Search

Indivior PLC

Abrir

1,242

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1242

Máximo

1242

Indicadores-chave

By Trading Economics

Rendimento

-19M

47M

Vendas

-33M

266M

P/E

Médio do Setor

330

38.156

Margem de lucro

17.669

Funcionários

1,030

EBITDA

-30M

76M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+10.23% upside

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

721M

1.5B

Abertura anterior

1242

Fecho anterior

1242

Indivior PLC Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

31 de jul. de 2025, 23:56 UTC

Ações em Alta

Stocks to Watch: Amazon, Bio-Rad, Coinbase, Mercer

31 de jul. de 2025, 23:48 UTC

Conversa de Mercado

Scentre Can Beat Annual Earnings Guidance -- Market Talk

31 de jul. de 2025, 23:45 UTC

Conversa de Mercado

Nikkei May Decline Amid Caution Over Earnings, Domestic Politics -- Market Talk

31 de jul. de 2025, 23:37 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

31 de jul. de 2025, 23:37 UTC

Conversa de Mercado

Gold Steady as Traders Eye Tariff-Deal Developments -- Market Talk

31 de jul. de 2025, 23:12 UTC

Ganhos

OCBC: Evolving Trade, Monetary Policies, Persistent Geopolitical Tensions Expected to Weigh on Growth Prospects >O39.SG

31 de jul. de 2025, 23:10 UTC

Ganhos

Oversea-Chinese Banking: Declining Interest-Rate Environment Weighed in Net Interest Income >O39.SG

31 de jul. de 2025, 23:09 UTC

Ganhos

Oversea-Chinese Banking 2Q Net Interest Income S$2.28B Vs. S$2.43B >O39.SG

31 de jul. de 2025, 23:08 UTC

Ganhos

Oversea-Chinese Banking 2Q Total Income S$3.55B Vs. S$3.63B >O39.SG

31 de jul. de 2025, 23:08 UTC

Ganhos

Oversea-Chinese Banking 2Q Net S$1.82B Vs. Net S$1.94B >O39.SG

31 de jul. de 2025, 23:01 UTC

Ganhos

Amazon Posts Higher Sales, Profit -- 3rd Update

31 de jul. de 2025, 22:08 UTC

Conversa de Mercado
Ganhos

Amazon CEO Impressed by Deals Signed for Project Kuiper -- Market Talk

31 de jul. de 2025, 22:02 UTC

Conversa de Mercado
Ganhos

Apple's FY Outlook Shows Sales Growth Won't Last -- Market Talk

31 de jul. de 2025, 21:57 UTC

Conversa de Mercado
Ganhos

Amazon CEO Sees Strong Early Demand for Alexa+ -- Market Talk

31 de jul. de 2025, 21:50 UTC

Ganhos

Amazon Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

31 de jul. de 2025, 21:43 UTC

Ganhos

Apple's iPhone Sales Blow Past Estimates as Customers Raced to Beat Tariffs -- 2nd Update

31 de jul. de 2025, 21:29 UTC

Ganhos

Amazon to Invest More in Chips, Data Centers Amid Generative AI Opportunity, CFO Says

31 de jul. de 2025, 21:26 UTC

Ganhos

Apple Expects Revenue to Grow in Mid- to High-Single Digits in Current Quarter, CFO Says

31 de jul. de 2025, 21:26 UTC

Ganhos

MicroStrategy Beats Earnings Estimates. The Stock Rises. -- Barrons.com

31 de jul. de 2025, 21:22 UTC

Ganhos

Amazon Has Impressive Amount of Agreements for Project Kuiper, CEO Says

31 de jul. de 2025, 21:19 UTC

Ganhos

Apple Estimates Tariff Impact to Add $1.1B to Costs in Current Quarter, CEO Says

31 de jul. de 2025, 21:19 UTC

Ganhos

Apple Incurred $800M in Tariff-Related Costs in 2Q, CEO Says

31 de jul. de 2025, 21:14 UTC

Ganhos

Amazon's AWS is Seeing More Demand Than Supply, CEO Says

31 de jul. de 2025, 21:12 UTC

Ganhos

Amazon Saw Record Prime Sign-Ups in 3 Weeks Before Prime Day, CEO Says

31 de jul. de 2025, 21:10 UTC

Ganhos

Amazon Just Getting Started on Automation, Robotics to Boost Efficiency, CEO Says

31 de jul. de 2025, 21:09 UTC

Ganhos

Amazon Delivered to Prime Members at Record Pace in 2Q, CEO Says

31 de jul. de 2025, 21:09 UTC

Ganhos

Amazon CEO Sees Diversity of Sellers as Advantage for Inflation-Weary Consumers

31 de jul. de 2025, 21:08 UTC

Ganhos

Apple iPhone Revenue Performance Driven by Popularity of iPhone 16 Family, CEO Says

31 de jul. de 2025, 21:08 UTC

Ganhos

Amazon CEO Sees Strong Customer Adoption of Perishables Same-Day Delivery Pilot

31 de jul. de 2025, 21:05 UTC

Ganhos

Apple's iPhone Sales Blow Past Estimates as Customers Raced to Beat Tariffs -- Update

Indivior PLC Previsão

Preço-alvo

By TipRanks

10.23% parte superior

Previsão para 12 meses

Média 1,364.65 GBX  10.23%

Máximo 1,637.581 GBX

Mínimo 967.662 GBX

Com base em 4 analistas de Wall Street que oferecem metas de preço de 12 meses para Indivior PLC - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

4 ratings

4

Comprar

0

Manter

0

Vender

Informação Financeira

$

Sobre Indivior PLC

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
help-icon Live chat